Genetic Risk, Coronary Heart Disease Events, and the Clinical Benefit of Statin Therapy: an Analysis of Primary and Secondary Prevention Trials

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2015 Mar 10

PMID 25748612

Citations 282

Authors

J L Mega

N O Stitziel

J G Smith

D I Chasman

M Caulfield

J J Devlin

F Nordio

C Hyde

C P Cannon

F Sacks

N Poulter

P Sever

P M Ridker

E Braunwald

O Melander

S Kathiresan

M S Sabatine

Affiliations

Soon will be listed here.

Abstract

Background: Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.

Methods: A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis.

Findings: When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was shown. Compared with the low genetic risk category, the multivariable-adjusted hazard ratio for coronary heart disease for the intermediate genetic risk category was 1·34 (95% CI 1·22-1·47, p<0·0001) and that for the high genetic risk category was 1·72 (1·55-1·92, p<0·0001). In terms of the benefit of statin therapy in the four randomised trials, we noted a significant gradient (p=0·0277) of increasing relative risk reductions across the low (13%), intermediate (29%), and high (48%) genetic risk categories. Similarly, we noted greater absolute risk reductions in those individuals in higher genetic risk categories (p=0·0101), resulting in a roughly threefold decrease in the number needed to treat to prevent one coronary heart disease event in the primary prevention trials. Specifically, in the primary prevention trials, the number needed to treat to prevent one such event in 10 years was 66 in people at low genetic risk, 42 in those at intermediate genetic risk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT.

Interpretation: A genetic risk score identified individuals at increased risk for both incident and recurrent coronary heart disease events. People with the highest burden of genetic risk derived the largest relative and absolute clinical benefit from statin therapy.

Funding: National Institutes of Health.

Citing Articles

Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.

Ponikowska M, Di Domenico P, Bolli A, Busby G, Perez E, Botta G Nutrients. 2025; 17(5).

PMID: 40077796 PMC: 11901995. DOI: 10.3390/nu17050926.

Revolutionising Cardio-Oncology Care with Precision Genomics.

Chong J, Chuah C, Lee C Int J Mol Sci. 2025; 26(5).

PMID: 40076674 PMC: 11900203. DOI: 10.3390/ijms26052052.

Additive association of blood group A allele with 15 cardiometabolic diseases: a UK Biobank life-course study.

Zhao R, Xian W, Ma Y, Napolioni V, Lau P, Tian X Cardiovasc Diabetol. 2025; 24(1):113.

PMID: 40065387 PMC: 11895148. DOI: 10.1186/s12933-025-02669-w.

Genome-wide association study of idiopathic epilepsy in the Italian Spinone dog breed.

Jenkins C, De Risio L, Lophatananon A, Lewis T, Foster D, Johnson J PLoS One. 2025; 20(3):e0315546.

PMID: 40043055 PMC: 11882058. DOI: 10.1371/journal.pone.0315546.

Endothelial cell-mediated risk of CAD could be used to target lipid-lowering therapy.

Nat Med. 2025; .

PMID: 40038509 DOI: 10.1038/s41591-025-03553-6.

References

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

Iakoubova O, Tong C, Chokkalingam A, Rowland C, Kirchgessner T, Louie J . Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arterioscler Thromb Vasc Biol. 2006; 26(12):2763-8. DOI: 10.1161/01.ATV.0000247248.76409.8b. View

Humphries S, Cooper J, Talmud P, Miller G . Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin Chem. 2006; 53(1):8-16. DOI: 10.1373/clinchem.2006.074591. View

Chiodini B, Franzosi M, Barlera S, Signorini S, Lewis C, DOrazio A . Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J. 2007; 28(16):1977-83. DOI: 10.1093/eurheartj/ehm196. View

Iakoubova O, Sabatine M, Rowland C, Tong C, Catanese J, Ranade K . Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008; 51(4):449-55. DOI: 10.1016/j.jacc.2007.10.017. View

Sabatine M, Ploughman L, Simonsen K, Iakoubova O, Kirchgessner T, Ranade K . Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol. 2008; 28(3):562-7. DOI: 10.1161/ATVBAHA.107.156653. View

Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt N, Roos C . Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008; 358(12):1240-9. DOI: 10.1056/NEJMoa0706728. View

der Zee A, Lynch A, Boerwinkle E, Arnett D, Davis B, Leiendecker-Foster C . Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of.... Pharmacogenet Genomics. 2008; 18(8):651-6. PMC: 2729516. DOI: 10.1097/FPC.0b013e3282fe1759. View

Tragante V, Doevendans P, Nathoe H, van der Graaf Y, Spiering W, Algra A . The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk. Eur Heart J. 2013; 34(37):2896-904. DOI: 10.1093/eurheartj/eht222. View

10.

Patel R, Asselbergs F, Quyyumi A, Palmer T, Finan C, Tragante V . Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events: a systematic review and meta-analysis. J Am Coll Cardiol. 2014; 63(21):2234-45. PMC: 4035794. DOI: 10.1016/j.jacc.2014.01.065. View

11.

Laufs U, Weintraub W, Packard C . Beyond statins: what to expect from add-on lipid regulating therapy?. Eur Heart J. 2013; 34(34):2660-5. DOI: 10.1093/eurheartj/eht213. View

12.

Ganna A, Magnusson P, Pedersen N, de Faire U, Reilly M, Arnlov J . Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013; 33(9):2267-72. DOI: 10.1161/ATVBAHA.113.301218. View

13.

Tikkanen E, Havulinna A, Palotie A, Salomaa V, Ripatti S . Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013; 33(9):2261-6. PMC: 4210840. DOI: 10.1161/ATVBAHA.112.301120. View

14.

Basso F, Lowe G, Rumley A, McMahon A, Humphries S . Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol. 2002; 22(4):599-604. DOI: 10.1161/01.atv.0000013283.84306.1a. View

15.

. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7-22. DOI: 10.1016/S0140-6736(02)09327-3. View

16.

Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre.... Lancet. 2003; 361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0. View

17.

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

18.

Lloyd-Jones D, Nam B, DAgostino Sr R, Levy D, Murabito J, Wang T . Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004; 291(18):2204-11. DOI: 10.1001/jama.291.18.2204. View

19.

Berglund G, Elmstahl S, Janzon L, Larsson S . The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med. 1993; 233(1):45-51. DOI: 10.1111/j.1365-2796.1993.tb00647.x. View

20.

Marenberg M, Risch N, Berkman L, Floderus B, de Faire U . Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994; 330(15):1041-6. DOI: 10.1056/NEJM199404143301503. View